We think the firm does face environmental, social, and governance risks, particularly related to US drug price-related policy changes (roughly 80% of Regeneron's revenue for top-selling drugs ...

Regeneron is also expanding its Tarrytown, New York-based facility and building a separate facility in the state to expand capacity to fill injection pens - a process known as fill-finish. Its ...

Regeneron has signed a collaboration deal ... with the lead party retaining global development and commercial responsibility. For CNS programs, both companies will have the option at candidate ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...